» Articles » PMID: 22993403

Dual Roles of PARP-1 Promote Cancer Growth and Progression

Abstract

Unlabelled: PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. PARP-1 has well-described functions in DNA damage repair and also functions as a context-specific regulator of transcription factors. With multiple models, data show that PARP-1 elicits protumorigenic effects in androgen receptor (AR)-positive prostate cancer cells, in both the presence and absence of genotoxic insult. Mechanistically, PARP-1 is recruited to sites of AR function, therein promoting AR occupancy and AR function. It was further confirmed in genetically defined systems that PARP-1 supports AR transcriptional function, and that in models of advanced prostate cancer, PARP-1 enzymatic activity is enhanced, further linking PARP-1 to AR activity and disease progression. In vivo analyses show that PARP-1 activity is required for AR function in xenograft tumors, as well as tumor cell growth in vivo and generation and maintenance of castration resistance. Finally, in a novel explant system of primary human tumors, targeting PARP-1 potently suppresses tumor cell proliferation. Collectively, these studies identify novel functions of PARP-1 in promoting disease progression, and ultimately suggest that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration resistance.

Significance: These studies introduce a paradigm shift with regard to PARP-1 function in human malignancy, and suggest that the dual functions of PARP-1 in DNA damage repair and transcription factor regulation can be leveraged to suppress pathways critical for promalignant phenotypes in prostate cancer cells by modulation of the DNA damage response and hormone signaling pathways. The combined studies highlight the importance of dual PARP-1 function in malignancy and provide the basis for therapeutic targeting.

Citing Articles

The Landscape of PARP Inhibitors in Solid Cancers.

Muzzana M, Broggini M, Damia G Onco Targets Ther. 2025; 18:297-317.

PMID: 40051775 PMC: 11884256. DOI: 10.2147/OTT.S499226.


Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.

Fanelli G, Nuzzo P, Pederzoli F, Loda M Surg Pathol Clin. 2025; 18(1):25-39.

PMID: 39890307 PMC: 11787547. DOI: 10.1016/j.path.2024.10.003.


Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.

Roberts H, Maurice-Dror C, Chi K Future Oncol. 2024; 21(2):201-211.

PMID: 39711161 PMC: 11792869. DOI: 10.1080/14796694.2024.2442900.


Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials.

Panebianco M, Cereda V, Dandrea M Explor Target Antitumor Ther. 2024; 5(5):997-1010.

PMID: 39351435 PMC: 11438558. DOI: 10.37349/etat.2024.00260.


AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D Oncogene. 2024; 43(43):3197-3213.

PMID: 39266679 PMC: 11493679. DOI: 10.1038/s41388-024-03148-4.


References
1.
Knudsen K, Scher H . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15(15):4792-8. PMC: 2842118. DOI: 10.1158/1078-0432.CCR-08-2660. View

2.
Huletsky A, de Murcia G, Muller S, Hengartner M, Menard L, Lamarre D . The effect of poly(ADP-ribosyl)ation on native and H1-depleted chromatin. A role of poly(ADP-ribosyl)ation on core nucleosome structure. J Biol Chem. 1989; 264(15):8878-86. View

3.
Schiewer M, Morey L, Burd C, Liu Y, Merry D, Ho S . Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene. 2008; 28(7):1016-27. PMC: 2852245. DOI: 10.1038/onc.2008.446. View

4.
Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

5.
Dean J, McClendon A, Hickey T, Butler L, Tilley W, Witkiewicz A . Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012; 11(14):2756-61. PMC: 3409015. DOI: 10.4161/cc.21195. View